Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in the Netherlands

被引:74
作者
de Greeff, Sabine C. [1 ]
Mooi, Frits R. [2 ]
Schellekens, Joop F. P. [3 ]
de Melker, Hester E. [1 ]
机构
[1] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands
[2] Natl Inst Publ Hlth & Environm, Lab Infect Dis & Screening, NL-3720 BA Bilthoven, Netherlands
[3] Infect Dis Lab, Groningen, Netherlands
关键词
pertussis; vaccination; epidemiology; The Netherlands;
D O I
10.1097/INF.0b013e318161a2b9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: An acellular preschool booster vaccination against pertussis has been included in the National Immunization Programme in The Netherlands, since November 2001. We studied the impact of this preschool booster on the epidemiology of pertussis. Methods: We analyzed and compared pertussis cases registered in the national notification system, hospital registry, and death registry between the periods 1998-2001 (without preschool booster) and 2002-2005 (with preschool booster). Results: In 2002-2005, the incidence of hospitalizations and notifications in 1-4 year olds were 48% and 44%, lower respectively, than in 1998-2001. Similarly, in 5-9 year olds the incidence of hospitalizations and notifications had decreased 32% and 15%, respectively. In 2005, vaccine effectiveness for preschool booster among children born between January 1, 1998 and January 1, 2001-all of whom had been eligible for the booster-was estimated at 79% (95% Cl: 71-85). In infants aged 0-6 months, the incidence of hospitalizations per 100,000 population decreased 40% from 222.5 to 133.6. In contrast, among cohorts aged 10-19, 20-59: and > 60 years, the incidence of notifications increased 60%, 44%, and 68%, respectively. Conclusions: The preschool booster strongly decreased the disease burden in the targeted cohorts. Importantly, the incidence in infants 0-6 months also showed a decline after introduction of the pre-school booster, suggesting reduced transmission from siblings to young infants. Meanwhile, the number of pertussis cases in adolescents and adults increased. With prevention of severe pertussis among infants as focus, this effect should not be ignored in the discussion on future vaccination strategies for pertussis.
引用
收藏
页码:218 / 223
页数:6
相关论文
共 38 条
[1]  
ABBINK F, 2005, IMMUNIZATION COVERAG
[2]   Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination [J].
Baron, S ;
Njamkepo, E ;
Grimprel, E ;
Begue, P ;
Desenclos, JC ;
Drucker, J ;
Guiso, N .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (05) :412-418
[3]   Infant pertussis - Who was the source? [J].
Bisgard, KM ;
Pascual, FB ;
Ehresmann, KR ;
Miller, CA ;
Cianfrini, C ;
Jennings, CE ;
Rebmann, CA ;
Gabel, J ;
Schauer, SL ;
Lett, SM .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (11) :985-989
[4]   Resurgence of pertussis in Europe [J].
Celentano, LP ;
Massari, M ;
Paramatti, D ;
Salmaso, S ;
Tozzi, AE .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (09) :761-765
[5]  
Center for Disease Control and Prevention [CDC], 2002, MMWR-MORBID MORTAL W, V49, P1
[6]   Immunity to pertussis [J].
Cherry, James D. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (10) :1278-1279
[7]   Recent developments in pertussis [J].
Crowcroft, Natasha S. ;
Pebody, Richard G. .
LANCET, 2006, 367 (9526) :1926-1936
[8]  
de Greeff S C, 2005, Ned Tijdschr Geneeskd, V149, P937
[9]   Reemergence of pertussis in the highly vaccinated population of the Netherlands:: Observations on surveillance data [J].
de Melker, HE ;
Schellekens, JFP ;
Neppelenbroek, SE ;
Mooi, FR ;
Rümke, HC ;
Conyn-van Spaendonck, MAE .
EMERGING INFECTIOUS DISEASES, 2000, 6 (04) :348-357
[10]   Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis [J].
de Melker, HE ;
Versteegh, FGA ;
Conyn-van Spaendonck, MAE ;
Elvers, LH ;
Berbers, GAM ;
van der Zee, A ;
Schellekens, JFP .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (02) :800-806